SecBot SecBot
8-K ·Filed May 5, 2026

STIM

Neuronetics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001193125-26-205117
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Revenue growth is positive but decelerating (8% vs 86% in Q4 2025) and gross margin compression signals mix headwinds. Cash burn remains heavy despite OpEx cuts. Maintain full-year guidance provides some stability, but the declining cash balance ($19M) and negative operating cash flow suggest a capital raise may be needed within 2-3 quarters. Watch for Q2 revenue trajectory and any financing announcements.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
STIM ▼ -9.22% at T+60d
NEUTRAL call -9.22% · α vs SPY -11.96% · entry $2.17 → $1.97
Entry = T+0 close
May 5, 2026
via day close
T+1d
-11.98%
call -11.98% · α -13.37%
$1.91
settled 6mo ago
T+5d
-30.65%
call -30.65% · α -32.63%
$1.51
settled 6mo ago
T+20d
-28.11%
call -28.11% · α -33.06%
$1.56
settled 5mo ago
T+60d
-9.22%
call -9.22% · α -11.96%
$1.97
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Neuronetics reported Q1 2026 revenue of $34.5M (+8% YoY) and a net loss of $(0.16)/share, slightly beating the $(0.17) consensus. Revenue growth was driven by 15% clinic revenue growth, but treatment session revenue declined 5% and gross margin contracted to 46.9% from 49.2%. The company maintained full-year 2026 guidance of $160M-$166M revenue, but cash burn remains significant with $19M total cash on hand. The prior restructuring (CEO transition, debt paydown) provides context but does not offset the mixed operating trends.

Key Financial Metrics

EPS
−$0.16
est −$0.17 · +5.9%
Revenue
$34.5M
est $34.2M · +0.7% · +7.8% YoY
Rating
in line
Guidance
$160M-$166M
maintained
Free Cash Flow
-$9.6M
Gross Margin
46.9%

Key Facts

  • Q1 2026 revenue $34.5M, up 8% YoY from $32.0M
  • Net loss $(10.8)M or $(0.16)/share vs $(12.7)M or $(0.21)/share in Q1 2025
  • EPS of $(0.16) beat consensus of $(0.17) by ~5.9%
  • Gross margin declined to 46.9% from 49.2% YoY due to mix shift
  • U.S. clinic revenue grew 15% to $21.5M; treatment session revenue fell 5% to $9.1M
  • Operating expenses decreased 6% to $25.1M from $26.8M
  • Total cash dropped to $19.0M from $34.1M at Dec 2025, after $5M debt prepayment
  • Full-year 2026 guidance maintained: revenue $160M-$166M, gross margin 47%-49%, operating cash flow $(13)M-$(17)M
  • Prior restructuring (CEO change, debt amendment, consulting agreement) filed 29 days ago

Financial Impact

Revenue beat consensus by ~$0.3M; EPS beat by $0.01. Cash burn of $9.4M in Q1 leaves $19M total cash, implying ~2 quarters of runway at current burn rate without additional financing.

revenueepsgross margincashoperating cash flow

Risk Factors

  • Cash burn: $9.4M operating cash outflow in Q1, leaving only $19M total cash
  • Gross margin compression: 46.9% vs 49.2% YoY, guided 47%-49% for FY2026
  • Treatment session revenue declining 5% YoY signals core NeuroStar utilization weakness
  • High debt load: $61.3M net long-term debt vs $13.3M equity
  • Restructuring context (CEO departure, debt amendment) suggests ongoing operational challenges

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-205117
Document: d139145d8k.htm0001193125-26-205117
Document: d139145dex992.htm0001193125-26-205117
Document: 0001193125-26-205117-index-headers.html0001193125-26-205117
Document: 0001193125-26-205117-index.html0001193125-26-205117
Document: 0001193125-26-205117.txt0001193125-26-205117
8-K Data (Synthetic)0001193125-26-205117
17 reports for STIM
Performance horizon
33% Hit rate @ T+1 2 of 6 directional calls Went positive at some point 3 of 6 best @ T+60▲ +2.96%Mar 17, 2026
Filters
Rows
Reports for STIM — sortable, filterable
TypeNow
Aug 11, 2026
10w ago
8-K
BULLISH ★ 6/10
$3.19 $3.21▲ +0.63%▲ +0.38%$2.24 (−29.78%)
Aug 11, 2026
10w ago
Press Release
BULLISH ★ 6/10
$3.19 $3.21▲ +0.63%▲ +0.38%$2.24 (−29.78%)
Jun 23, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$1.26 $1.27▲ +0.79%▲ +0.65%$2.24 (+77.78%)
May 22, 2026
22w ago
8-K
NEUTRAL ★ 2/10
$1.20 $1.22▲ +1.67%▲ +1.08%$2.24 (+86.67%)
May 5, 2026
24w ago
8-K
MIXED ★ 6/10
$2.17 $1.91▼ −11.98%▼ −13.37%$2.24 (+3.23%)
May 5, 2026
24w ago
Press Release
NEUTRAL ★ 5/10
$2.17 $1.91▼ −11.98%▼ −13.37%$2.24 (+3.23%)
Apr 21, 2026
26w ago
Press Release
NEUTRAL ★ 1/10
$1.50 $1.59▲ +6.00%▲ +4.98%$2.24 (+49.33%)
Apr 13, 2026
28w ago
EFFECT
BEARISH ★ 7/10
$1.39 $1.43▼ −2.88%▼ −1.67%$2.24 (−61.15%)
Mar 19, 2026
31w ago
Insider Cluster
BULLISH ★ 6/10
$1.52 $1.45▼ −4.29%▼ −2.55%$2.24 (+47.85%)
Mar 19, 2026
31w ago
Insider Cluster
BULLISH ★ 7/10
$1.52 $1.45▼ −4.29%▼ −2.55%$2.24 (+47.85%)
Showing 10 of 17

US Market Status

Market Closed — Opens Tue (16h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026